Tenax Therapeutics

Filed a patent for "use of a combination of levosimendan and an sglt-2 inhibitor to treat heart failure" on Wed, May 29, 2024

Filed a patent for "levosimendan for treating pulmonary hypertension heart failure with preserved ejection fraction (ph-hfpef)" on Thu, August 15, 2024

Filed a patent for "levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)" on Thu, April 6, 2023